Skip to main content

Mercury Therapeutics Licenses Dartmouth Protein Kinase IP to Millipore

NEW YORK (GenomeWeb News) - Mercury Therapeutics said yesterday that it has granted Millipore exclusive worldwide rights to human AMP-activated protein kinase in the field of research products and services.

The AMPK patent was originally licensed by Mercury Therapeutics in 2000 from Dartmouth College. The patent is based on research by Dartmouth professor Lee Witters and his collaborator Bruce Kemp from the St. Vincent's Institute for Medical Research in Melbourne, Australia.

The transaction includes an undisclosed upfront license fee, royalties on net sales, and sharing of all sublicense revenue for the life of the agreement, Mercury said.

Mercury, based in Woburn, Mass., develops AMPK activators as therapeutics for type 2 diabetes, oncology, and cardiovascular disease.

"This association with Millipore promises to advance significantly the field of AMPK-directed therapies," Witters said in a statement.

Alla Kan, director of Dartmouth's Technology Transfer Office, added that the technology "has always been seen by us as one of our crown jewels, and now with this exciting development, its time has come."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.